EP1954823A1 - Cited4 en tant que marqueur de pronostic dans des tumeurs oligodendrogliales - Google Patents

Cited4 en tant que marqueur de pronostic dans des tumeurs oligodendrogliales

Info

Publication number
EP1954823A1
EP1954823A1 EP06818908A EP06818908A EP1954823A1 EP 1954823 A1 EP1954823 A1 EP 1954823A1 EP 06818908 A EP06818908 A EP 06818908A EP 06818908 A EP06818908 A EP 06818908A EP 1954823 A1 EP1954823 A1 EP 1954823A1
Authority
EP
European Patent Office
Prior art keywords
nucleic acid
acid sequence
cited4
sequence
inventive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06818908A
Other languages
German (de)
English (en)
Inventor
Björn Tews
Peter Lichter
Peter Roerig
Andreas Von Deimling
Meinhard Hahn
Guido Reifenberger
Jörg FELSBERG
Christian Hartmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Priority to EP06818908A priority Critical patent/EP1954823A1/fr
Publication of EP1954823A1 publication Critical patent/EP1954823A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne de nouveaux procédés (de diagnostic) de détection du cancer du système nerveux central, de préférence d'oligodendrogliomes, en détectant la présence de séquences d'acides nucléiques CITED4 dans un échantillon biologique. La présente invention concerne en outre un procédé (de diagnostic) servant à déterminer le degré de méthylation de la région promotrice du gène CITED4 dans un échantillon biologique. L'invention concerne, dans un mode de réalisation supplémentaire, un procédé pour la thérapie génique convenant pour traiter ou prévenir des cancers du système nerveux central, de préférence des oligodendrogliomes. Enfin, l'invention concerne aussi des séquences d'acides nucléiques, des séquences d'acides aminés, des vecteurs, des compositions pharmaceutiques et des kits, convenant dans ces procédés de l'invention.
EP06818908A 2005-11-30 2006-11-29 Cited4 en tant que marqueur de pronostic dans des tumeurs oligodendrogliales Withdrawn EP1954823A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06818908A EP1954823A1 (fr) 2005-11-30 2006-11-29 Cited4 en tant que marqueur de pronostic dans des tumeurs oligodendrogliales

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05026117A EP1793003A1 (fr) 2005-11-30 2005-11-30 CITED4 en tant que marqueur de pronostic pour les tumeurs oligodendrogliales
PCT/EP2006/011460 WO2007062827A1 (fr) 2005-11-30 2006-11-29 Cited4 en tant que marqueur de pronostic dans des tumeurs oligodendrogliales
EP06818908A EP1954823A1 (fr) 2005-11-30 2006-11-29 Cited4 en tant que marqueur de pronostic dans des tumeurs oligodendrogliales

Publications (1)

Publication Number Publication Date
EP1954823A1 true EP1954823A1 (fr) 2008-08-13

Family

ID=36499630

Family Applications (2)

Application Number Title Priority Date Filing Date
EP05026117A Withdrawn EP1793003A1 (fr) 2005-11-30 2005-11-30 CITED4 en tant que marqueur de pronostic pour les tumeurs oligodendrogliales
EP06818908A Withdrawn EP1954823A1 (fr) 2005-11-30 2006-11-29 Cited4 en tant que marqueur de pronostic dans des tumeurs oligodendrogliales

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP05026117A Withdrawn EP1793003A1 (fr) 2005-11-30 2005-11-30 CITED4 en tant que marqueur de pronostic pour les tumeurs oligodendrogliales

Country Status (2)

Country Link
EP (2) EP1793003A1 (fr)
WO (1) WO2007062827A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10772974B2 (en) * 2013-11-18 2020-09-15 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for cardiac regeneration
CN115948544B (zh) * 2023-03-08 2023-05-16 中国中医科学院望京医院(中国中医科学院骨伤科研究所) Cited4和/或metrn在椎间盘退变程度的鉴别诊断中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0006572D0 (en) * 2000-03-17 2000-05-10 Isis Innovation Novel transcription transactivator protein
AU2002244055A1 (en) * 2001-02-12 2002-08-28 The Penn State Research Foundation Fra-1 expression in brain cancer
GB0126386D0 (en) * 2001-11-02 2002-01-02 Isis Innovation Screening methods based on cited family proteins
JP2007516693A (ja) * 2003-06-09 2007-06-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 癌の治療および診断のための組成物および方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007062827A1 *

Also Published As

Publication number Publication date
EP1793003A1 (fr) 2007-06-06
WO2007062827A1 (fr) 2007-06-07

Similar Documents

Publication Publication Date Title
EP2740742B1 (fr) Gène chimère de gène kif5b et de gène ret, et procédé de détermination de l'efficacité d'un traitement anticancéreux ciblant le gène chimère
EP2456889B1 (fr) Marqueurs du cancer de l'endometre
EP1824997B1 (fr) Alterations genetiques utiles pour predire la response de neoplasies malignes a des traitements medicaux bases sur le taxane
CN105980576B (zh) 用于源自乳腺癌的骨转移癌的预后和治疗的方法
JP2010525301A (ja) 子宮内膜癌および前癌の診断、分類および治療の方法
KR20150122731A (ko) 암 전이의 예후 및 치료 방법
US20110262464A1 (en) Compositions, Kits, and Methods for the Diagnosis, Prognosis, and Monitoring of Cancer Using GOLPH3
JP2004159640A5 (ja) 悪性腫瘍の予測、診断、予後判定、予防および治療のための方法および組成物
US9494591B2 (en) Mutations of histone proteins associated with proliferative disorders
US20120052079A1 (en) Compositions, Kits, and Methods for Predicting Anti-Cancer Response to Anthracyclines
US20120277110A1 (en) Parp and adjuvant cisplatin-based chemotherapy in non-small-cell lung cancer
US8216783B2 (en) Over-expression and mutation of a tyrosine kinase receptor FGFR4 in tumors
Kim et al. Suppression of putative tumour suppressor gene GLTSCR2 expression in human glioblastomas
WO2014135655A1 (fr) Compositions et méthodes de traitement du cancer de la vessie invasif pour le muscle
EP1793003A1 (fr) CITED4 en tant que marqueur de pronostic pour les tumeurs oligodendrogliales
WO2014154898A1 (fr) Pronostic et traitement des cancers
US20030092042A1 (en) Amplified oncogenes and their involvement in cancer
KR20050004076A (ko) 암의 평가 및 치료 방법
Barok et al. Characterization of a novel, trastuzumab resistant human breast cancer cell line
US20030099985A1 (en) Amplified gene involved in cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080523

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TEWS, BJOERN

Inventor name: HARTMANN, CHRISTIAN

Inventor name: VON DEIMLING, ANDREAS

Inventor name: LICHTER, PETER

Inventor name: ROERIG, PETER

Inventor name: FELSBERG, JOERG

Inventor name: HAHN, MEINHARD

Inventor name: REIFENBERGER, GUIDO

17Q First examination report despatched

Effective date: 20081002

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100316